Third Quarter 2025 Earnings Call

November 3, 2025

Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.

Third quarter 2025 performance and highlights

Making strong progress guided by strategic growth pillars

- **Focus on the Cancer Care Continuum (CCC) to accelerate growth**
- **Grow revenue at or above market in Prenatal Health and Mental Health**
- **Focus on sustained profitable growth**

Improving execution as shown in Q3 volume growth

Q3 ‘25 revenue of $205.7 million reflects:

- **11%** growth YOY in hereditary cancer test volume
- **8%** GeneSight volume growth YOY
- **Positive** Prolaris test volume growth YOY

Generating strong profitability

70.1% adj. gross margin in Q3 ‘25

Managed discretionary spend effectively in Q3 ‘25 as adj. operating expenses decreased $1 million YOY

$10.3 million adj. EBITDA in Q3 ‘25

$0.00 adj. EPS in Q3 ‘25

Reiterating 2025 financial guidance range reflecting Q3 results and anticipated business trends through year-end

Myriad genetics®

Strategic pillars to accelerate profitable growth

Focus on the Cancer Care Continuum (CCC) to accelerate growth

Grow revenue at or above market in Prenatal Health and Mental Health

Focus on sustained profitable growth

What will be different going forward?

- **Focused Investments**
  Prioritized focus, funding and resourcing of the CCC strategy
- **CCC Portfolio**
  Beyond HCT and HRD; providing compelling offerings for other potential high-growth cancer testing applications including MRD
- **Strategic Partnerships**
  Beyond Myriad developed products; leveraging strategic partnerships that complement Myriad's differentiated capabilities to serve attractive market opportunities in a timely manner
- **Right Team**
  Deep domain knowledge and proven experience
- **Execution Excellence**
  Elevated urgency, strengthened processes, rigor and discipline

Update on Cancer Care Continuum strategic pillar

Focus on the Cancer Care Continuum (CCC) to accelerate growth

Grow revenue at or above market in Prenatal Health and Mental Health

Focus on sustained profitable growth

- **SOPHiA GENETICS** partnership for liquid biopsy – Q3 ‘25
- Updated **MyRisk HCT** ~ Q4 ’25
- **Precise MRD** for breast ~ H1 ’26
- **AI-enabled Prolaris** powered by **PATHOMIQ** partnership ~ H1 ’26

Update on strategic pillars #2 and #3

Focus on the Cancer Care Continuum (CCC) to accelerate growth

Grow revenue at or above market in Prenatal Health and Mental Health

Focus on sustained profitable growth

- **FirstGene** early access going well; full commercial launch expected in 2026
- **GeneSight** volume growth Mid-to-High Single Digits
- Implementing changes designed to improve customer experience, gain market share, and reduce operating expense as a percentage of revenue

Myriad genetics

Mark Verratti

CHIEF OPERATING OFFICER

Oncology

Third quarter 2025 and recent highlights

- Q3 ’25 Hereditary cancer testing revenue in Oncology grew 2% YOY driven by 9% volume growth YOY
- Q3 ‘25 Prolaris revenue grew 3% YOY, reflecting stability; expect commercial launch of AI-enabled Prolaris in 1H ’26
- Collaboration with SOPHiA GENETICS
- Ultrasensitive performance of Myriad’s MRD test, Precise® MRD, highlighted in recent article[1] in The Lancet Oncology

Operational results

$81.8M
Q3 ’25 revenue

~55k
Q3 ‘25 volume

Key Performance Highlights

MyRisk affected

8%	16%
Revenue growth[1]	Volume growth[1]

1. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00380-8

1: Q3 ‘25 Growth (YOY)

Building on our gold standard hereditary cancer risk testing franchise



MyRisk® Hereditary Cancer Test | with **RiskScore®**

- **Only panel that meets NCCN familial high-risk assessment and ASCO strongly recommended genes guidelines**
- Adding 15 genes to the MyRisk panel to analyze risk of developing 11 types of hereditary cancer
- Polygenic test for women of all ancestries
- Increased accuracy in estimating woman's lifetime risk of developing breast cancer
- >95 papers published and growing

Expanded MyRisk Hereditary Cancer Test launch targeted November 2025

Women's Health

Third quarter 2025 and recent highlights

- Q3 ’25 Hereditary cancer testing revenue in unaffected population grew 4% YOY driven by 11% volume growth YOY
- Q3 ’25 prenatal revenue growth reflects gradual recovery from Q2 ’25, as expected; positive experience in early access sites for FirstGene™ Multiple Prenatal Screen
- In October 2025, Myriad expanded its Foresight Universal Plus Panel, which now includes all conditions recommended by the American College of Medical Genetics and Genomics for prenatal screening.

Operational results

$85.2M
Q3 ’25 revenue

~194k
Q3 ‘25 volume

Key Performance Highlights

Foresight and Prequel

5%	**0%**
Revenue growth[1]	Volume growth[1]

Myriad genetics

1: Q3 ‘25 growth (YOY)

Transformative prenatal screen running multiple tests at once

Current CHALLENGES with prenatal genetic screening

Providers don't have enough time to talk about genetics

Only **50% utilization** of carrier screening[1]

Only **30% of fathers** get screened when mother is a carrier[2]

Low gross margins on **NIPS** and **ECS**

Our SOLUTION

FirstGene™
Multiple Prenatal Screen

- NIPS
- Carrier Screening
- Fetal recessive status
- Blood compatibility

- Easier for providers to administer integrated offering
- No need to screen the father
- Improved gross margins

1 Pereira et al, J Assist Reprod Geneti 2019 Apr; 36(4): 709-716
2 Arjunan et al, Prenat. Diagn. 2021 Jun; 41(7):896-904

Myriad genetics®

Third quarter 2025 and recent highlights

- GeneSight test volume grew 8% YOY, an on-going growth acceleration from Q1 ’25, reflecting initiatives implemented
- Excluding UnitedHealthcare, Q3 ‘25 average revenue per GeneSight test grew compared to Q2 ‘25

GeneSight®
Mental Health Medication Test

Operational results

$38.7M
Q3 ’25 revenue

~136k
Q3 ‘25 volume

37k+
Number of clinicians that ordered GeneSight in Q3 ’25 (a record high)

Ben Wheeler

CHIEF FINANCIAL OFFICER

Myriad genetics®

Third quarter 2025 financial performance

Improving test volume growth and discretionary spend management

All figures in millions, except per share amounts and percentages

Total revenue



Adjusted Gross Margin*



Adjusted Operating Expense*



Adjusted EPS*



*GAAP to non-GAAP reconciliations for Q3 '24 and Q3 '25 can be found in the Appendix.

Myriad genetics

Profitability and liquidity

All figures in millions, except percentages

Adjusted Gross Profit[1]



Adjusted EBITDA[1]

Achieved

$10.3 million

As of Q3 '25

Liquidity position

Access to

$220.4 million

cash and cash equivalents + option to expand credit facility ($75 million)

As of Q3 '25

Q3 '25 adj. operating cash flow[1] was $24.8 million

Q3 '25 adj. free cash flow[1] of $18.6 million

1 GAAP to non-GAAP reconciliations can be found in the Appendix..

Taking actions designed to drive strategic growth

Building a strong, scalable team focused on the Cancer Care Continuum

Enhance Commercial focus on the Cancer Care Continuum

- Reinvest to drive strategic growth
- Leverage leadership in Hereditary Cancer Testing
- Expand sales reach in the Cancer Care Continuum

Examples of ongoing investment programs focused on enhancing commercial capabilities

Expansion of our commercial organization
- Meaningful increase in field sales team
- Optimizing structure and territory design

Deliver better overall user experience
- Increase support tools for commercial launches and market activation programs

Increase funding for strategic R&D programs
- Clinical studies for MRD as well as other areas

Myriad has commenced a multi-year program to invest

>$35M

in its commercial capabilities addressing the Cancer Care Continuum. This investment will primarily be funded by the company's focus on structure and efficiency

Reiterate 2025 financial guidance

All figures in millions, except per share amounts and percentages

	2025 Current (as of November 3, 2025)
Total revenue	$818 - $828
Gross margin %	69.5% – 70.0%
Adj. operating expenses*	$562 - $568
Adj. EBITDA*	$27 – $33
Adj. EPS*	$(0.02) - $0.02

*The company does not forecast GAAP operating expenses, earnings before interest, tax, depreciation, or amortization (EBITDA), and earnings per share because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation and the Appendix to this presentation for more information about the use of non-GAAP financial measures.

Assumes currency rates as of November 3, 2025.

Myriad genetics

Our commitment to breast cancer care

>30 Years

Myriad has been committed to Breast Cancer

>2 Million

Total number of MyRisk test results provided to-date



* Expect to start offering Precise MRD test for clinical use in the first half of 2026.

OCTOBER IS
BREAST CANCER
AWARENESS MONTH

Myriad genetics®

Q&A

Myriad genetics®

Appendix

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted Gross Margin

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
Adjusted Gross Margin				
Gross Profit	$ 143.8	$ 149.8	$ 429.8	$ 434.5
Acquisition - amortization of intangible assets(1)	—	0.3	0.6	1.2
Equity compensation(2)	0.3	0.3	0.9	0.9
Other adjustments(3)	—	0.1	0.3	0.5
Adjusted Gross Profit	$ 144.1	$ 150.5	$ 431.6	$ 437.1
Adjusted Gross Margin	70.1 %	70.6 %	70.2 %	69.7 %

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees.

(3) Other one-time non-recurring expenses for the three and nine months ended September 30, 2025 and September 30, 2024.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted Operating Expenses

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
Adjusted Operating Expenses				
Operating Expenses	$ 167.1	$ 169.8	$ 811.3	$ 519.0
Acquisition - amortization of intangible assets(1)	(6.5)	(10.0)	(23.4)	(30.6)
Goodwill and long-lived asset impairment(2)	—	(2.2)	(316.7)	(13.8)
Equity compensation(3)	(11.9)	(12.0)	(31.5)	(37.6)
Real estate optimization(4)	—	(2.0)	(5.2)	(5.5)
Transformation initiatives(5)	—	(2.6)	—	(6.6)
Strategic realignment(6)	(8.3)	—	(10.1)	—
Legal settlements(7)	—	—	—	(0.5)
Other adjustments(8)	(0.4)	—	—	(3.5)
Adjusted Operating Expenses	$ 140.0	$ 141.0	$ 424.4	$ 420.9

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted Operating Expenses (Cont.)

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Expense related to goodwill and long-lived asset impairment. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Pharmacogenomics and Women's Health reporting units and asset groups. For the three and nine months ended September 30, 2024, consists of impairment expense primarily related to the sale of the EndoPredict business to Eurobio Scientific.

(3) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(4) Costs related to real estate initiatives. For the three and nine months ended September 30, 2024, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South Francisco, California, while maintaining our previous facilities in those locations, costs associated with the voluntary termination of a lease, testing and set-up costs for equipment in our new facilities, and impairment in connection with the ceased use of one of our facilities.

(5) Costs related to transformation initiatives including consulting and professional fees for the three and nine months ended September 30, 2024.

(6) Costs related to strategic realignment of the company including severance and consulting fees for the three and nine months ended September 30, 2025. Prior-period amounts ($1.8 million for the six months ended June 30, 2025) have been reclassified from "Other one-time expenses" to conform to the current presentation in this reconciliation.

(7) Costs related to one-time legal expenses, net of reimbursement for the nine months ended September 30, 2024.

(8) Other one-time non-recurring expenses. For the three and nine months ended September 30, 2025, consists of other adjustments. As noted above, $1.8 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the six months ended June 30, 2025 were reclassified to strategic realignment in this reconciliation. For the three and nine months ended September 30, 2024, primarily includes a gain recognized on acquisition, changes in the fair value of contingent consideration related to acquisitions from prior years, the reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity, and costs incurred in connection with executive personnel changes.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted Net Income

(unaudited data in millions, except per share amounts)

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
Adjusted Net Income[1]				
Net Loss	$ (27.4)	$ (22.1)	$ (358.0)	$ (84.8)
Acquisition - amortization of intangible assets[2]	6.5	10.3	24.0	31.5
Goodwill and long-lived asset impairment[3]	—	2.2	316.7	13.8
Equity compensation[4]	12.2	12.3	32.4	38.9
Real estate optimization[5]	—	2.0	5.2	5.5
Transformation initiatives[6]	—	2.6	—	6.6
Strategic realignment[7]	8.3	—	10.1	—
Legal settlements[8]	—	—	—	0.5
Other adjustments[9]	0.4	0.1	0.4	2.5
Uncertain tax benefit[10]	—	—	(29.0)	—
Tax adjustments[11]	0.2	(2.1)	0.1	(5.2)
Adjusted Net Income	$ 0.2	$ 5.3	$ 1.9	$ 9.3
Weighted average shares outstanding:				
Diluted	93.8	92.6	93.2	91.9
Adjusted Earnings Per Share				
Diluted	$ —	$ 0.06	$ 0.02	$ 0.10

Myriad genetics

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted Net Income (Cont.)

(1) To determine Adjusted Earnings Per Share, or adjusted EPS.

(2) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(3) Expense related to goodwill and long-lived asset impairment. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Pharmacogenomics and Women's Health reporting units and asset groups. For the three and nine months ended September 30, 2024, consists of impairment expense primarily related to the sale of the EndoPredict business to Eurobio Scientific.

(4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(5) Costs related to real estate initiatives. For the three and nine months ended September 30, 2024, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South Francisco, California, while maintaining our previous facilities in those locations, costs associated with the voluntary termination of a lease, testing and set-up costs for equipment in our new facilities, and impairment in connection with the ceased use of one of our facilities.

(6) Costs related to transformation initiatives including consulting and professional fees for the three and nine months ended September 30, 2024.

(7) Costs related to strategic realignment of the company including severance and consulting fees for the three and nine months ended September 30, 2025. Prior-period amounts ($1.8 million for the six months ended June 30, 2025) have been reclassified from “Other one-time expenses” to conform to the current presentation in this reconciliation.

(8) Costs related to one-time legal expenses, net of reimbursement for the nine months ended September 30, 2024.

(9) Other one-time non-recurring expenses. For the three and nine months ended September 30, 2025, consists of other adjustments. As noted above, $1.8 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the six months ended June 30, 2025 were reclassified to strategic realignment in this reconciliation. For the three and nine months ended September 30, 2024, primarily includes a gain recognized on acquisition, changes in the fair value of contingent consideration related to acquisitions from prior years, the reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity, and costs incurred in connection with executive personnel changes.

(10) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended September 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.

(11) Tax expense or benefit due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. As of September 30, 2025, a valuation allowance of $104.8 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance. As of September 30, 2024, a valuation allowance of $63.1 million was not recognized for non-GAAP purposes given the company's historical and forecasted positive earnings performance.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted EBITDA

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
Adjusted EBITDA				
Net Loss	$ (27.4)	$ (22.1)	$ (358.0)	$ (84.8)
Acquisition - amortization of intangible assets[1]	6.5	10.3	24.0	31.5
Depreciation expense[2]	4.8	4.4	14.8	13.2
Goodwill and long-lived asset impairment[3]	—	2.2	316.7	13.8
Equity compensation[4]	12.2	12.3	32.4	38.9
Real estate optimization[5]	—	2.0	5.2	5.5
Transformation initiatives[6]	—	2.6	—	6.6
Strategic realignment[7]	8.3	—	10.1	—
Legal settlements[8]	—	—	—	0.5
Interest expense, net of interest income[9]	3.3	0.4	5.1	0.7
Other adjustments[10]	1.4	1.1	2.5	3.6
Uncertain tax benefits[11]	—	—	(29.0)	—
Income tax expense[12]	1.2	0.9	0.8	0.4
Adjusted EBITDA	$ 10.3	$ 14.1	$ 24.6	$ 29.9

Myriad genetics

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted EBITDA (Cont.)

(1) Represents recurring amortization charges resulting from the acquisition of intangible assets.

(2) Depreciation expense excludes depreciation included in real estate optimization of $0.4 million and $1.3 million for the three and nine months ended September 30, 2024, respectively.

(3) Expense related to goodwill and long-lived asset impairment. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Pharmacogenomics and Women's Health reporting units and asset groups. For the three and nine months ended September 30, 2024, consists of impairment expense primarily related to the sale of the EndoPredict business to Eurobio Scientific.

(4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors.

(5) Costs related to real estate initiatives. For the three and nine months ended September 30, 2024, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South Francisco, California, while maintaining our previous facilities in those locations, costs associated with the voluntary termination of a lease, testing and set-up costs for equipment in our new facilities, and impairment in connection with the ceased use of one of our facilities.

(6) Costs related to transformation initiatives including consulting and professional fees for the three and nine months ended September 30, 2024.

(7) Costs related to strategic realignment of the company including severance and consulting fees for the three and nine months ended September 30, 2025. Prior-period amounts ($1.8 million for the six months ended June 30, 2025) have been reclassified from "Other one-time expenses" to conform to the current presentation in this reconciliation.

(8) Costs related to one-time legal expenses, net of reimbursement for the nine months ended September 30, 2024.

(9) Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations.

(10) Other one-time non-recurring expenses. For purposes of adjusted EBITDA, this includes Other adjustments described in Adjusted Net Loss above as well as the amounts reported as Other income (expense) in the Condensed Consolidated Statement of Operations. See also Note 7 above regarding the reclassification of other adjustments to transformation initiatives.

(11) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended September 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released.

(12) Derived from income tax expense (benefit) from the Condensed Consolidated Statement of Operations, net of the adjustment for unrecognized tax benefits described above in Note 10.

Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2025 and 2024 – Adjusted Free Cash Flow

(unaudited data in millions)

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
Adjusted operating and free cash flow				
Net cash provided by (used in) operating activities	$ 21.1	$ 0.7	$ (8.8)	$ (15.3)
Real estate optimization[1]	1.2	2.5	8.7	11.7
Transformation initiatives[2]	2.3	2.6	4.1	6.6
Legal settlements[3]	—	—	—	0.6
Contingent consideration payment[4]	—	—	—	5.8
Other adjustments[5]	0.2	—	0.2	3.5
Adjusted operating cash flow	$ 24.8	$ 5.8	$ 4.2	$ 12.9
Capital expenditures[6]	(2.8)	(3.5)	(10.9)	(15.4)
Capitalization of internal-use software costs [6]	(3.4)	(2.8)	(10.5)	(8.4)
Adjusted free cash flow	$ 18.6	$ (0.5)	$ (17.2)	$ (10.9)

(1) The cash flow effect of real estate optimizations, excluding non-cash items such as accelerated depreciation.

(2) Transformation initiatives includes the cash paid for those costs in the related periods. During the three months ended September 30, 2025, management determined that severance costs that had previously been reported in other one-time expenses should be reported as part of our transition efforts. Consequently $1.8 million in severance costs that were reported as other adjustments in our reconciliations of GAAP to Non-GAAP financial measures for the six months ended June 30, 2025 were reclassified to transformation initiatives in this reconciliation.

(3) The cash flow effect of legal expense in the related period.

(4) The payment of contingent consideration related to the previous acquisition of Sividon Diagnostics GmbH.

(5) The cash flow effect of executive personnel changes and severance in the related periods. See also Note 6 above regarding the reclassification of other adjustments to transformation initiatives.

(6) Derived from the Condensed Consolidated Statements of Cash Flows.